News

David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.

Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.

Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

PT217 is a first-in-class treatment targeting DLL3 and CD47 for patients with extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.

Debra Patt, MD, PhD, MBA, discussed the ways oncologists can ensure a bright future for themselves and their patients through embracing technology.

Rivoceranib did not produce a statistically significant improvement in overall survival vs placebo, according to findings from the phase 3 ANGEL trial in gastric or gastroesophageal junction cancer.

Using neoadjuvant atezolizumab followed by atezolizumab plus chemotherapy before surgery for gastric or gastroesophageal junction tumors appeared to be effective and warrants further study.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

In an interview with Targeted Oncology, Kim N. Chi, MD, FRCPC, discussed the MAGNITUDE trial results, including patient-reported outcomes, in patients with BRCA-positive mCRPC.

SH-201 is a new, promising option for certain types of leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia, as well as other cancers.

Revumenib shows promise in treating both adults and children with specific types of leukemia, with similar safety and effectiveness.

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

Emerging NK-cell therapies offer faster, safer alternatives to CAR T-cell therapy, improving accessibility and reducing manufacturing challenges. T-DXd shows promise in treating HER2+ tumors, and HPV vaccine offerings during abortion care visits improve vaccination rates.

Though osimertinib is the preferred frontline approach to treatment for those with non-small cell lung cancer with classic EGFR mutations, acquired resistance mechanisms invariably develop.

An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.

The approval follows a unanimous vote by the FDA’s Oncologic Drugs Advisory Committee where they decided the benefits of cilta-cel outweigh the risks for this patient population.

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients. 

Fam-trastuzumab deruxtecan-nxki received accelerated approval from the FDA for adult patients with unresectable or metastatic HER2-positive solid tumors.

Regina Barragan-Carrillo, MD, discusses an abstract which evaluated the association between thymectomy and incidence of renal cell carcinoma.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.

Idecabtagene vicleucel (ide-cel) demonstrated a 51% reduction in risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Recommendations for non–small cell lung cancer biomarker testing in early-stage disease were discussed in a presentation regarding metastatic lung cancer by Christine M. Lovly, MD, PhD.

Kim N. Chi, MD, FRCPC, discusses the significance of the phase 3 MAGNITUDE trial, including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer.

Immune checkpoint inhibitor-based treatment was equally effective as a frontline treatment for both Black and White patients with metastatic renal cell carcinoma in separate analyses.

Findings from recent clinical research have firmly entrenched the use of neoadjuvant immune checkpoint blockade in the treatment of early-stage non-small cell lung cancer.